All News

AHCA.jpg

ACR Backs the Provider Reimbursement Stability Act

ACR

The American College of Rheumatology (ACR) today thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and protect patient access to care.

Read Article
smartphone

Physician Use of Augmented Intelligence has Doubled

Jack Cush, MD

A 2026 Physician Survey to assess artificial intelligence and its use in Medical Practice has been published and follows earlier surveys around adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling meaningful trend analysis. AI adoption has more than doubled in three years and physician sentiment shifting decisively toward cautious optimism.

Read Article
computer.health.jpg (keep)

Modest Benefits with AI Scribes on EHR Documentation

EurekAlert!

Documenting a patient visit in the electronic health record (EHR) is essential to healthcare delivery, but also a major contributor to clinician burnout.

Read Article
myositis.jpg

Screening High Risk Myositis Patients for Cancer

Jack Cush, MD

An Italian retrospective study of 411 idiopathic inflammatory myopathies (IIM) patients applied IMACS criteria to assess the risk of cancer and found significantly more cancers in those at high risk.

Read Article
RheumNow Podcast square

Top Four and More (4.10.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.

Read Article
pills-14550__180_0.jpg

Opioids Down, Gabapentins Up

Jack Cush, MD

The number of U.S. patients prescribed long-term opioid therapy declined from 2015 to 2023, but co-prescribing of opioids with gabapentinoids increased, prescription data showed.

Read Article
Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab vs 19 not. Betw group outcomes same: PFTs, O2 use, Infx, Resp admissions, mortality. RTX group recv more immunosuppressives. https://t.co/sle4a0JOFL https://t.co/SyhK12KhHY

Links:

Dr. John Cush RheumNow ( View Tweet)
Top Four and More (4.10.2026) Dr. Jack Cush reviews the news and journal reports from RheumNow this week - including his top four favorite subjects. https://t.co/TUPky5m1Mo https://t.co/QRgh9SqcOF

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Guideline on the Management of Crohn Disease https://t.co/GV0lICS8Sn https://t.co/aFWH5Tl4Jv

Links:

Dr. John Cush RheumNow ( View Tweet)
“Math has no opinion” - Mellody Hobson

Dr. John Cush RheumNow ( View Tweet)

Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/A3wb3pzbl3

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Our Future Health study of 1,563,155 finds affective Dz (depression, bipolar, anxiety) signific higher (p<0.001)in autoimmune pts vs gen. pop. (29% vs 18%) - dx by PHQ-9, GAD-7. (OR 1.86), even after adjustments income and pain, etc. https://t.co/HoKBeAZxbS https://t.co/NtJhaf7WCo

Links:

Dr. John Cush RheumNow ( View Tweet)
Italian retrospective study 411 IIM pts classified cancer risk per IMACS criteria: 44% high-, 38% intermed- 18% standard-risk. 9.2% had CA w/in 3yrs. Signif more in high-risk (OR 4.05). CA predictors: TIF1γ (OR  12.3), SAE1 (OR = 11.9) https://t.co/j4gA0g79bI https://t.co/Pt5nMs89bl

Links:

Dr. John Cush RheumNow ( View Tweet)
COMMON - Incidental Rotator Cuff Abnormalities on MRI In this cross-sectional study of 602 Finnish adults undergoing bilateral shoulder magnetic resonance imaging (MRI) and clinical assessment, abnormalities were found in nearly everyone over age 40 years, regardless of whether https://t.co/2n58lglVP0
Dr. John Cush RheumNow ( View Tweet)
Hopkins Myositis study of 637 dermatomyositis pts - FLARES were assoc w/ DM Dz activity; manifest as rash (76%), motor weakness (58%), Pulm (19%), arthritis (12%). O nly 2–5% of Flare pts had cancer Dx w/in 6–24-mos https://t.co/AKC9oIKAS7 https://t.co/26q8FfkUfl

Links:

Dr. John Cush RheumNow ( View Tweet)
Among neuro-ophthalmic complications of Immune Checkpoint Inhibitors, myasthenia gravis (often with concomitant myositis) is most common irAE, followed by optic neuropathy (often as optic neuritis) https://t.co/7pxqSKY3M1 https://t.co/bisbShFHIc

Links:

Dr. John Cush RheumNow ( View Tweet)
VEXAS Syndrome - A Review Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies. https://t.co/Nik0TJm6Qu https://t.co/WS35PRnbBv

Links:

Dr. John Cush RheumNow ( View Tweet)
Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z https://t.co/yEgB6ImDTi

Links:

Dr. John Cush RheumNow ( View Tweet)
From 2015 to 2023, long-term opioid therapy declined in the USA. Approximately 4 million to 5 million patients were prescribed long-term opioid therapy in 2023. Long term opioid use remains a challenge https://t.co/N5s7mYvXSw https://t.co/YHdTbHLB4q

Links:

Dr. John Cush RheumNow ( View Tweet)
Single-centre retrosp study of established 257 PMR pts. 98 referred by GPs were for Dx uncertainty (51 vs 14%), less for relapse (27%) or recurrence (11%). PMR Dx accuracy better by Rheums vs PCPs (83% v 62%, P < 0.05) https://t.co/DvTKeuGa4Q https://t.co/wQDXR46k5F

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×